Innovation Pharmaceuticals Inc (IPIX)

[steelyeye]

Since we're all speculating, it is fascinating to read some always hammering out the worst case scenarios at every turn.

What's been (conveniently) left-out so far is that IPIX retains the right to repurchase all these preferred shares at a slight premium, and the funders may have already received material non-public information that encouraged them to make the funding deal happen in the first place, and pronto.

Just imagine... Leo has the trials set up and a major deal waiting in the wings upon good enough interim results. And interim results should not take very long, given the need, urgency and availability of both testing sites and patients.

At the very least, the company's announcing commencement of the coming phase 2 clinical trial should generate quite a bit of interest, given results from previous phase 2 clinical trails using Brilacidin, combined with the stellar RBL study results for C-19.

My speculation is that the above scenario is "almost certainly" the case.

How many other compounds have an SI of 426?

The difference between the two is almost certainly the number of shares sold to Aspire in the interim period.